Suppr超能文献

益生菌制剂治疗特发性口臭的疗效:回顾性观察研究。

Therapeutic efficacy of a probiotic preparation on idiopathic halitosis: a retrospective observational study.

作者信息

Li Ye Kan, Mou Fu Yuan, Qian Xiao Xian

机构信息

Department of Stomatology, Minhang Hospital, Fudan University, Shanghai, People's Republic of China.

Halitosis Clinic and Department of Gastroenterology, Minhang Hospital, Fudan University, Shanghai, People's Republic of China.

出版信息

J Breath Res. 2024 Nov 12;19(1). doi: 10.1088/1752-7163/ad8e7e.

Abstract

Idiopathic halitosis is an unusual condition of unclear causes, which has never been thoroughly investigated. We aimed to explore the role of small intestinal bacterial overgrowth (SIBO) in the pathogenesis of idiopathic halitosis, and to evaluate the therapeutic efficacy of a probiotic preparation on this condition. This retrospective observational study included 162 idiopathic halitosis patients and 198 healthy controls (HCs). Halitosis was diagnosed using the organoleptic test, and idiopathic halitosis was diagnosed by excluding known causes. SIBO was identified through the hydrogen/methane lactulose breath test, and accordingly, patients were identified as SIBO-positive or SIBO-negative. Idiopathic halitosis patients were treated with the probiotic preparationtriple viable capsule for two months, followed by re-evaluation of halitosis and SIBO. This study found that all cases of idiopathic halitosis were extra-oral. The SIBO positivity rate in idiopathic halitosis patients was significantly higher than that in HCs (74.69% [121/162] vs 3.03% [6/198],< 0.001), with an odds ratio of 94.44% (95% CI: 39.99%-211.35%). After treatment, 80.17% (97/121) of the SIBO-positive patients became SIBO-negative. Moreover, 87.60% (106/121) of the SIBO-positive patients experienced improved halitosis, a rate significantly higher than that observed in SIBO-negative patients (2.75%, 3/41) (< 0.001). In addition, 98.97% (96/97) of the post-treatment SIBO-negative patients experienced improved halitosis, a rate significantly higher than that of post-treatment sustained SIBO-positive patients (41.67%, 10/24) (< 0.001). Our findings suggest that idiopathic halitosis is an extra-oral condition which mostly originates from the small intestine. SIBO is one of its underlying causes. The probiotic preparation can effectively improve idiopathic halitosis, probably through its impact on SIBO.

摘要

特发性口臭是一种病因不明的罕见病症,从未得到过彻底的研究。我们旨在探讨小肠细菌过度生长(SIBO)在特发性口臭发病机制中的作用,并评估益生菌制剂对此类疾病的治疗效果。本回顾性观察性研究纳入了 162 例特发性口臭患者和 198 例健康对照者(HCs)。使用嗅觉测试诊断口臭,通过排除已知病因诊断为特发性口臭。通过氢/甲烷乳果糖呼气试验鉴定 SIBO,据此将患者分为 SIBO 阳性或 SIBO 阴性。特发性口臭患者使用三联活菌胶囊治疗两个月,然后重新评估口臭和 SIBO。本研究发现,所有特发性口臭病例均为口腔外来源。特发性口臭患者的 SIBO 阳性率明显高于 HCs(74.69%[121/162] vs. 3.03%[6/198],<0.001),优势比为 94.44%(95%CI:39.99%-211.35%)。治疗后,80.17%(97/121)的 SIBO 阳性患者 SIBO 转为阴性。此外,87.60%(106/121)的 SIBO 阳性患者口臭得到改善,这一比例明显高于 SIBO 阴性患者(2.75%,3/41,<0.001)。此外,98.97%(96/97)治疗后 SIBO 阴性的患者口臭得到改善,这一比例明显高于治疗后持续 SIBO 阳性的患者(41.67%,10/24,<0.001)。我们的研究结果表明,特发性口臭是一种口腔外疾病,主要起源于小肠。SIBO 是其病因之一。益生菌制剂可以有效改善特发性口臭,可能是通过对 SIBO 的影响。

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验